Selective anticancer activity of the novel steroidal dihydropyridine spirooxindoles against human esophageal EC109 cells.
A series of small-molecule compounds built on steroidal dihydropyridine spirooxindoles has been reported previously. In this study, the compound 5l showed strong anti-cancer activity, especially in the esophageal cancer. Three esophageal squamous cell lines and paclitaxel-resistant cell line were investigated. The results demonstrated that compound 5l was most efficient in the EC109 cells, induced cell apoptosis through elevation of cellular ROS levels, caused G2/M phase arrest and mitochondrial dysfunction. Further study confirmed that the mechanism of 5l in esophageal cancer treatment was related to the Bcl-2 family and caspase receptor-mediated apoptotic pathway.
['Shi|Xiaoli|X|', 'Qin|Tiantian|T|', 'Liu|Weihua|W|', 'Zhang|Xueyan|X|', 'Li|Leilei|L|', 'Huo|Junfeng|J|', 'Zhou|Kairui|K|', 'Yang|Dongxiao|D|', 'Zhang|Yanling|Y|', 'Wang|Cong|C|']
D000972:Antineoplastic Agents, Phytogenic D017209:Apoptosis D002294:Carcinoma, Squamous Cell D059447:Cell Cycle Checkpoints D045744:Cell Line, Tumor D004095:Dihydropyridines D004351:Drug Resistance D004938:Esophageal Neoplasms D059565:G2 Phase Cell Cycle Checkpoints D006801:Humans D017239:Paclitaxel D019253:Proto-Oncogene Proteins c-bcl-2 D017382:Reactive Oxygen Species D054852:Small Molecule Libraries
Esophageal cancer Antiproliferative activity Mechanistic studies Steroidal dimmer